Sentences with phrase «researched endocrine cancer»

Not exact matches

However, other research has suggested that the estrogen - like effects of isoflavones may reduce the effectiveness of endocrine therapies used to treat breast cancer.
The researchers, including scientists from The Genome Institute at Washington University School of Medicine, presented the research titled, «Patient - derived xenograft study reveals endocrine therapy resistance of ER + breast cancer caused by distinct ESR1 gene aberrations.»
If the tumor is large or there's obvious evidence that the cancer is in the lymph nodes, you take them out,» said author Julie Ann Sosa, M.D., chief of endocrine surgery and leader of the endocrine neoplasia diseases group at the Duke Clinical Research Institute and the Duke Cancer Instcancer is in the lymph nodes, you take them out,» said author Julie Ann Sosa, M.D., chief of endocrine surgery and leader of the endocrine neoplasia diseases group at the Duke Clinical Research Institute and the Duke Cancer InstCancer Institute.
Her research areas included breast cancer, endocrine disruption and tissue engineering.
SEATTLE, Feb. 05, 2018 (GLOBE NEWSWIRE)-- NanoString Technologies, Inc. (NASDAQ: NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced the publication of a landmark study in which Danish researchers used the Prosigna ® Breast Cancer Assay risk of recurrence (ROR) score to accurately predict rates of 10 - year distant recurrence (DR) of cancer in a comprehensive and population - based cohort including all postmenopausal women in Denmark with early - stage hormone receptor (HR)- positive, Her - 2 negative breast cancer who received 5 years of adjuvant endocrine therapy according to nationwide guidelines between 2000 andCancer Assay risk of recurrence (ROR) score to accurately predict rates of 10 - year distant recurrence (DR) of cancer in a comprehensive and population - based cohort including all postmenopausal women in Denmark with early - stage hormone receptor (HR)- positive, Her - 2 negative breast cancer who received 5 years of adjuvant endocrine therapy according to nationwide guidelines between 2000 andcancer in a comprehensive and population - based cohort including all postmenopausal women in Denmark with early - stage hormone receptor (HR)- positive, Her - 2 negative breast cancer who received 5 years of adjuvant endocrine therapy according to nationwide guidelines between 2000 andcancer who received 5 years of adjuvant endocrine therapy according to nationwide guidelines between 2000 and 2003.
Canine and human comparisons represent an unprecedented opportunity to complement conventional endocrine tumour research paradigms, addressing a devastating group of cancers for which innovative diagnostic and treatment strategies are clearly needed.
She has also obtained a Breast Cancer Research Foundation American Association for Cancer Research (BCRF - AACR) Grant for Translational Breast Cancer Research to explore combined endocrine and ErbB inhibition in ER + / HER2 + breast cancers in 2007, a K23 Career Development Award to explore targeted therapies in breast cancer, and is also co-Leader in three of the four research projects of the NCI - funded Vanderbilt Breast Cancer Specialized Program of Research Excellence (SPORE; Carlos Arteaga, DireCancer Research Foundation American Association for Cancer Research (BCRF - AACR) Grant for Translational Breast Cancer Research to explore combined endocrine and ErbB inhibition in ER + / HER2 + breast cancers in 2007, a K23 Career Development Award to explore targeted therapies in breast cancer, and is also co-Leader in three of the four research projects of the NCI - funded Vanderbilt Breast Cancer Specialized Program of Research Excellence (SPORE; Carlos Arteaga, DiResearch Foundation American Association for Cancer Research (BCRF - AACR) Grant for Translational Breast Cancer Research to explore combined endocrine and ErbB inhibition in ER + / HER2 + breast cancers in 2007, a K23 Career Development Award to explore targeted therapies in breast cancer, and is also co-Leader in three of the four research projects of the NCI - funded Vanderbilt Breast Cancer Specialized Program of Research Excellence (SPORE; Carlos Arteaga, DireCancer Research (BCRF - AACR) Grant for Translational Breast Cancer Research to explore combined endocrine and ErbB inhibition in ER + / HER2 + breast cancers in 2007, a K23 Career Development Award to explore targeted therapies in breast cancer, and is also co-Leader in three of the four research projects of the NCI - funded Vanderbilt Breast Cancer Specialized Program of Research Excellence (SPORE; Carlos Arteaga, DiResearch (BCRF - AACR) Grant for Translational Breast Cancer Research to explore combined endocrine and ErbB inhibition in ER + / HER2 + breast cancers in 2007, a K23 Career Development Award to explore targeted therapies in breast cancer, and is also co-Leader in three of the four research projects of the NCI - funded Vanderbilt Breast Cancer Specialized Program of Research Excellence (SPORE; Carlos Arteaga, DireCancer Research to explore combined endocrine and ErbB inhibition in ER + / HER2 + breast cancers in 2007, a K23 Career Development Award to explore targeted therapies in breast cancer, and is also co-Leader in three of the four research projects of the NCI - funded Vanderbilt Breast Cancer Specialized Program of Research Excellence (SPORE; Carlos Arteaga, DiResearch to explore combined endocrine and ErbB inhibition in ER + / HER2 + breast cancers in 2007, a K23 Career Development Award to explore targeted therapies in breast cancer, and is also co-Leader in three of the four research projects of the NCI - funded Vanderbilt Breast Cancer Specialized Program of Research Excellence (SPORE; Carlos Arteaga, Direcancer, and is also co-Leader in three of the four research projects of the NCI - funded Vanderbilt Breast Cancer Specialized Program of Research Excellence (SPORE; Carlos Arteaga, Diresearch projects of the NCI - funded Vanderbilt Breast Cancer Specialized Program of Research Excellence (SPORE; Carlos Arteaga, DireCancer Specialized Program of Research Excellence (SPORE; Carlos Arteaga, DiResearch Excellence (SPORE; Carlos Arteaga, Director).
Autism Epidemic Gut Microbes & Digestive Disorders Some Statistics Endocrine Disruption, Cancer and Kidney Failure New GMO Research Summary.
a b c d e f g h i j k l m n o p q r s t u v w x y z